The Latest Analyst Ratings for ResMed
Portfolio Pulse from Benzinga Insights
In the last quarter, ResMed (NYSE:RMD) received 2 bullish and 4 somewhat bullish ratings from analysts. No bearish or indifferent ratings were given. The company's average 12-month price target is $273.5, with a high of $290.00 and a low of $250.00. This average price target has increased by 0.74% over the past month.
August 14, 2023 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ResMed received positive ratings from analysts, with an average 12-month price target of $273.5, indicating potential upside.
Analyst ratings are a significant factor that investors consider when making investment decisions. The positive ratings and the increase in the average price target for ResMed suggest that analysts are optimistic about the company's future performance, which could lead to an increase in its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100